67 related articles for article (PubMed ID: 17559380)
1. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
[TBL] [Abstract][Full Text] [Related]
2. NON-INVASIVE METHODS OF DIAGNOSTICS OF GASTRO-ESOPHAGEAL REFLUX DISEASE IN PATIENTS WITH ISCHEMIC HEART DISEASE.
Derbak MA; Tovtun RI; Horlenko OM; Hanych OT; Timashev VV; Lukach PM; Hechko M
Wiad Lek; 2023; 76(11):2372-2377. PubMed ID: 38112351
[TBL] [Abstract][Full Text] [Related]
3. Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Tang M; Blake KV; Lima JJ; Mougey EB; Franciosi J; Schmidt S; Hossain MJ; Cobbaert M; Fischer BM; Lang JE
Contemp Clin Trials; 2019 Mar; 78():27-33. PubMed ID: 30659924
[TBL] [Abstract][Full Text] [Related]
4. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the effectiveness of rabeprazole original and generic products in the monotherapy of gastroesophageal reflux disease].
Krapivnaia OV
Ter Arkh; 2023 Oct; 95(8):670-673. PubMed ID: 38158903
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study.
Kinoshita Y; Kusano M; Iwakiri K; Fujishiro M; Tachikawa N; Haruma K
Curr Ther Res Clin Exp; 2018; 88():26-34. PubMed ID: 30038671
[TBL] [Abstract][Full Text] [Related]
7. Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.
Kyler KE; Gaedigk A; Abdel-Rahman S; Staggs VS; Pearce RE; Toren P; Leeder JS; Shakhnovich V
Clin Transl Sci; 2024 Apr; 17(4):e13782. PubMed ID: 38629502
[TBL] [Abstract][Full Text] [Related]
8. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
9. Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis.
Zhang M; Pandolfino JE; Zhou X; Tan N; Li Y; Chen M; Xiao Y
Therap Adv Gastroenterol; 2019; 12():1756284819890537. PubMed ID: 31803253
[TBL] [Abstract][Full Text] [Related]
10. Associations of Circulating Gut Hormone and Adipocytokine Levels with the Spectrum of Gastroesophageal Reflux Disease.
Tseng PH; Yang WS; Liou JM; Lee YC; Wang HP; Lin JT; Wu MS
PLoS One; 2015; 10(10):e0141410. PubMed ID: 26506614
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drug interactions with proton pump inhibitors.
Scott SA; Owusu Obeng A; Hulot JS
Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):175-89. PubMed ID: 24205916
[TBL] [Abstract][Full Text] [Related]
12. Strategy for treatment of nonerosive reflux disease in Asia.
Hiyama T; Yoshihara M; Tanaka S; Haruma K; Chayama K
World J Gastroenterol; 2008 May; 14(20):3123-8. PubMed ID: 18506915
[TBL] [Abstract][Full Text] [Related]
13. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes.
Tseng PH; Lee YC; Chiu HM; Wang HP; Lin JT; Wu MS
J Clin Gastroenterol; 2009; 43(10):920-5. PubMed ID: 19407662
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
[TBL] [Abstract][Full Text] [Related]
16. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenomical aspects of gastroesophageal reflux disease].
Isaev VA
Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
